Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MedWellAI (MWAI) Shares Outstanding (Weighted Average) (2016 - 2025)

MedWellAI (MWAI) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $5.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 17.43% to $5.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $5.9 million, a 17.43% increase, with the full-year FY2024 number at $4.4 million, up 96.43% from a year prior.
  • Shares Outstanding (Weighted Average) was $5.9 million for Q1 2025 at MedWellAI, up from $5.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $204.3 million in Q4 2021 to a low of $1.6 million in Q2 2022.
  • A 5-year average of $46.7 million and a median of $4.3 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 173.04% in 2021, then tumbled 99.12% in 2022.
  • MedWellAI's Shares Outstanding (Weighted Average) stood at $204.3 million in 2021, then plummeted by 99.07% to $1.9 million in 2022, then skyrocketed by 122.81% to $4.2 million in 2023, then rose by 20.06% to $5.1 million in 2024, then rose by 17.14% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for MWAI's Shares Outstanding (Weighted Average) are $5.9 million (Q1 2025), $5.1 million (Q3 2024), and $4.4 million (Q2 2024).